Abstract
We have discovered that the P/Q-type voltage-gated Ca2+ channel (VGCC) gene, CACNA1A, encodes both the α1A (Cav2.1) subunit and a newly recognized transcription factor, α1ACT, by means of a novel internal ribosomal entry site (IRES) within the α1A C-terminal coding region. α1ACT, when mutated with an expansion of the polyglutamine tract in the C-terminus, gives rise to spinocerebellar ataxia type 6 (SCA6). Because silencing of the entire CACNA1A gene would result in the loss of the essential Cav2.1 channel, the IRES controlling α1ACT expression is an excellent target for selective silencing of α1ACT as a therapeutic intervention for SCA6. We performed a high-throughput screen of FDA-approved small molecules using a dual luciferase reporter system and identified ten hits able to selectively inhibit the IRES. We identified four main candidates that showed selective suppression of α1ACT relative to α1A in HEK cells expressing a native CACNA1A vector. We previously pursued another avenue of molecular intervention through miRNA silencing. We studied three human miRNAs (miRNA-711, -3191-5p, -4786) that would potentially bind to sequences within the CACNA1A IRES region, based on an miRNA prediction program. Only miRNA-3191-5p was found to selectively inhibit the translation of α1ACT in cells. We developed a hyperacute model of SCA6 in mice by injecting a pathogenic form of the IRES-mediated α1ACT (AAV9-α1ACTQ33). Finally, we tested the effectiveness of the miRNA therapy by co-expressing either control miRNA or miRNA-3191-5p and found that miRNA-3191-5p decreased the levels of α1ACTQ33 and prevented the hyperacute disease in mice. These studies provide the proof of principle that a therapy directed at selectively preventing α1ACT expression could be used to treat SCA6.
References
Solodkin A, Gomez CM. Spinocerebellar ataxia type 6. Handb Clin Neurol. 2012;103:461–73. https://doi.org/10.1016/B978-0-444-51892-7.00029-2.
Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha1A-voltage-dependent calcium channel. Nat Genet. 1997;15(1):62–9. https://doi.org/10.1038/ng0197-62.
Jun K, Piedras-Renteria ES, Smith SM, et al. Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci U S A. 1999;21:15245–50.
Du X, Wang J, Zhu H, Rinaldo L, Lamar KM, Palmenberg AC, et al. A second cistron in the CACNA1A gene encodes a transcription factor that mediates cerebellar development and SCA6. Cell. 2013;154(1):118–33. https://doi.org/10.1016/j.cell.2013.05.059.
Watase K, Barrett CF, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, et al. Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc Natl Acad Sci U S A. 2008;105(33):11987–92. https://doi.org/10.1073/pnas.0804350105.
Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S, et al. Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci. 2007;34(2):261–70. https://doi.org/10.1016/j.mcn.2006.11.006.
Kordasiewicz HB, Thompson RM, Clark HB, Gomez CM. C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum Mol Genet. 2006;15(10):1587–99. https://doi.org/10.1093/hmg/ddl080.
Martinez-Salas E, Pineiro D, Fernandez N. Alternative mechanisms to initiate translation in eukaryotic mRNAs. Comp Funct Genomics. 2012;2012:1–12. https://doi.org/10.1155/2012/391546.
Karginov TA, Pastor Hejazi DP, Semler BL, et al. Mammalian polycistronic mRNAs and disease. Trends Genet. 2017;33(2):129–42. https://doi.org/10.1016/j.tig.2016.11.007.
MacFarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–61. https://doi.org/10.2174/138920210793175895.
Miyazaki Y, Du X, Muramatsu S, et al. An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Sci Transl Med. 2016;8:347–94.
Rolf S, Bruns HJ, Wichter T, et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J. 2003;24:1085–6.
Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol Biol Cell. 1997;8(6):973–85. https://doi.org/10.1091/mbc.8.6.973.
Begleiter A, Mowat M, Israels LG, et al. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma. 1996;3:187–201.
Porter JB, Rafique R, Srichairatanakool S, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci. 2005;1054(1):155–68. https://doi.org/10.1196/annals.1345.018.
Lim KRQ, Maruyama R, Tokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–45. https://doi.org/10.2147/DDDT.S97635.
Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;8:890–7.
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, de Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–26. https://doi.org/10.1016/S0140-6736(16)31408-8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pastor, P.D.H., Du, X., Fazal, S. et al. Targeting the CACNA1A IRES as a Treatment for Spinocerebellar Ataxia Type 6. Cerebellum 17, 72–77 (2018). https://doi.org/10.1007/s12311-018-0917-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12311-018-0917-6